CompanyNuminus Wellness Inc.
Canada
Numinus Wellness Inc., a cannabis technology company, engages in biomass sourcing, extraction, and manufacture of cannabis in Canada. The company also operates laboratories for analytic testing of cannabis; and offers health related services.
Private/Public:
public
Phone:+1 833-686-4687
Website:https://numinus.com/
Address:33 Water St Suite 801, Vancouver, BC V6B 1R4, Canada
1962
Since
1
Country
0
Top Service Category
0
Sub-Service Category
Top Services
Canada
- (10.Jun.2022) Numinus Completes Acquisition of Novamind and Announces Executive Appointments
- (08.Jun.2022) Numinus Announces Shareholder Approval of Resolution in Connection With the Proposed Acquisition of Novamind
- (31.May.2022) Numinus Announces ISS Recommends Shareholders Vote in Favor of the Share Issuance to Acquire Novamind
- (16.May.2022) Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-Assisted Therapy Treatment
- (11.May.2022) Novamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of Arrangement
- (10.May.2022) Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement
- (12.Apr.2022) Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
- (30.Mar.2022) Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
- (14.Mar.2022) Numinus Expands Natural Psychedelic Research With New Biosecurity License
- (09.Mar.2022) Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
- (28.Feb.2022) Numinus Wellness Announces Voting Results From Its Annual General and Special Meeting of Shareholders
- (27.Jan.2022) Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
- (19.Jan.2022) Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
- (14.Jan.2022) Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
- (07.Jan.2022) Numinus Announces Q1 2022 Results Conference Call Update
- (22.Dec.2021) Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
- (16.Dec.2021) Numinus Wellness Opens the Market
- (29.Nov.2021) Numinus Develops Proprietary Psychedelic Tests With New Toxicity and Potency Scans
- (26.Nov.2021) Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange
- (25.Nov.2021) Numinus Announces Departure of Stacey Wallin
- (19.Nov.2021) Numinus to Begin Trading on the OTC Under Symbol NUMIF
- (10.Nov.2021) Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
- (20.Oct.2021) Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
- (08.Oct.2021) Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
- (08.Oct.2021) Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
- (23.Sep.2021) Numinus Completes Acquisition of Neurology Centre of Toronto
- (29.Jul.2021) Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion Into Psychedelic Neurology
- (12.Jul.2021) Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
- (06.Jul.2021) Numinus Wellness to Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology